The Europe Spatial Genomics & Transcriptomics Market was valued at $127.28 Million in 2024 and projected to reach to $213.79 Million by 2029, representing a compound annual growth rate of 10.9%. Europe's spatial genomics and transcriptomics market is positioned for sustained growth through 2029, driven by increasing investments in precision medicine and genomic research infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe's spatial genomics and transcriptomics market is valued at $127.28 million in 2024, with a projected expansion to $213.79 million by 2029, representing a robust 10.9% CAGR driven by precision medicine adoption.
Germany dominates Europe's market with $83.4 million in 2024, leveraging its world-class research institutions and advanced healthcare infrastructure to drive innovation in spatial genomics technologies.
The UK ($56.4 million) and France ($32.75 million) are significant contributors, supported by strong government funding for genomic research initiatives and established biotech ecosystems across both nations.
Europe's established healthcare systems, academic research centers, and regulatory frameworks create a competitive advantage for spatial genomics adoption and clinical implementation across the region.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Visium and Xenium platforms enable spatial gene expression analysis in intact tissues for oncology research, cellular mapping, biomarker discovery, and tissue heterogeneity studies. | Enables high-resolution spatial profiling | Supports cellular and tissue-level analysis | Facilitates biomarker discovery and translational research |
|
|
The CosMx Spatial Molecular Imager enables high-plex spatial RNA analysis to investigate cellular interactions, tumor microenvironments, and gene expression in oncology, neuroscience, and immunology. | Enables detailed spatial gene expression analysis | Preserves tissue architecture | Supports investigation of cellular interactions and disease mechanisms |
|
|
Sequencing platforms and reagents support sequencing-based spatial transcriptomics workflows for tissue profiling, disease research, biomarker discovery, and translational studies. | Supports high-throughput sequencing and downstream spatial data analysis | Enables gene expression profiling | Facilitates integration of spatial transcriptomics with broader genomic research |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 12.4% from 2024 to 2029 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 0.56 (2024) |
| Revenue Forecast (Billions) | ~USD 0.9957 (2029) |
| Segments Covered | Offering, Type, Technique, Application, End User |
5 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 1.9 | 2.9 | 3.1 | 3.5 | 4 | 4.6 | 5.4 | 6.2 | 14.6 |
| OTHER END USERS | 0.7 | 1.1 | 1.2 | 1.3 | 1.5 | 1.7 | 2 | 2.3 | 14.3 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 0.8 | 1.3 | 1.4 | 1.6 | 1.9 | 2.2 | 2.5 | 2.9 | 15.3 |
| TOTAL | 3.4 | 5.4 | 5.8 | 6.5 | 7.4 | 8.5 | 9.9 | 11.5 | 14.7 |
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 54.9 | 80 | 81.8 | 87.6 | 96.2 | 106.7 | 120.1 | 135.7 | 10.7 |
| CLINICAL DIAGNOSTIC LABORATORIES | 2 | 2.9 | 3.1 | 3.3 | 3.7 | 4.2 | 4.7 | 5.4 | 12.2 |
| CROS & CDMOS | 16.8 | 24.4 | 24.9 | 26.5 | 29 | 32 | 35.9 | 40.5 | 10.2 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 11.3 | 16.8 | 17.5 | 19.2 | 21.5 | 24.3 | 27.9 | 32.1 | 12.9 |
| TOTAL | 84.9 | 124.1 | 127.3 | 136.6 | 150.4 | 167.2 | 188.6 | 213.8 | 10.9 |
| Country | 2025 size (native) |
|---|---|
| Germany | USD 83.4 Million |
| UK | USD 56.4 Million |
| France | USD 32.75 Million |
| Italy | USD 11.84 Million |
| Spain | USD 9.66 Million |
| Rest Of Europe | USD 44.55 Million |
Europe's spatial genomics and transcriptomics market was valued at $127.28 million in 2024 and is projected to reach $213.79 million by 2029.
Europe's spatial genomics market is expected to grow at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2029.
Germany, the United Kingdom, France, and Switzerland are the primary drivers of Europe's spatial genomics market growth through research investments and biotech innovation.
Europe's market growth is driven by substantial government funding, collaborative research networks, regulatory support for precision medicine, and strong academic-industry partnerships.
Oncology, neurology, and immunology are the primary clinical applications driving spatial transcriptomics adoption across Europe's healthcare and research sectors.
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global spatial genomics & transcriptomics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the spatial genomics & transcriptomics market. The secondary sources referred to for this research study include publications from government sources, such as the World Health Organization (WHO), National Institutes of Health (NIH), Organisation for Economic Co-operation and Development (OECD), International Agency for Research on Cancer (IARC), Research!America, Genome Canada, GenomeWeb, South African Medical Research Council (SAMRC), Wellcome Sanger Institute, Genome Research Limited, Labiotech.eu, R&D World Magazine, India Brand Equity Foundation (IBEF), Biotechnology Innovation Organization (BIO), National Center for Biotechnology Information (NCBI), BioPharm International, EvaluatePharma, ScienceDirect, and Eurostat, among others.
Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements), business magazines and research journals, press releases, and trade, business, and professional associations. Secondary data was collected and analyzed to determine the overall size of the global market, which was validated through primary research.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

To know about the assumptions considered for the study, download the pdf brochure
The top-down and bottom-up approaches were used to estimate & validate the total size of the spatial genomics & transcriptomics market. These methods were also used extensively to estimate the size of various market segments.

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.
Spatial genomics and transcriptomics are pioneering technologies that allow scientists to measure gene activity in a tissue sample and map the site of the activity. Spatial transcriptomics helps spatially resolve RNA-seq data and all mRNAs in individual tissue sections. The technology is presently used in translational research and can be used in clinical diagnosis in the future. Spatial genomics also helps map gene expression across human tissues.
The scope of the market encompasses the tools, technologies, and services used to explore the spatial distribution and organization of genetic material and gene expression within cells and tissues.
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
Company Information
Full forecast, segment splits, and company analysis for all Spatial Genomics & Transcriptomics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report